In vitro evaluation of the Twincer colistin dry powder inhaler as a non-cough-inducing alternative to Colobreathe Source: International Congress 2016 – Clinical and microbiological aspects of bronchiectasis and non-tuberculous mycobacterium (NTM) infections Year: 2016
Efficacy and safety of ciprofloxacin dry powder for inhalation in patients with non-cystic fibrosis bronchiectasis Source: Annual Congress 2011 - Advances in antibiotic therapy of non-cystic fibrosis bronchiectasis Year: 2011
Evaluation of inhaled dry powder tobramycin free base in non-cystic fibrosis bronchiectasis patients Source: International Congress 2016 – Clinical and microbiological aspects of bronchiectasis and non-tuberculous mycobacterium (NTM) infections Year: 2016
Antimicrobial efficacy of ciprofloxacin dry powder for inhalation in patients with non-cystic fibrosis bronchiectasis Source: Annual Congress 2011 - Advances in antibiotic therapy of non-cystic fibrosis bronchiectasis Year: 2011
Once-daily budesonide: clinical equivalence of two dry powder inhalers (DPIs) Source: Eur Respir J 2005; 26: Suppl. 49, 339s Year: 2005
Inhaled dry powder mannitol in cystic fibrosis: an efficacy and safety study Source: Eur Respir J 2011; 38: 1071-1080 Year: 2011
Clinical equivalence of budesonide delivered via two dry powder inhalers Source: Eur Respir J 2005; 26: Suppl. 49, 339s Year: 2005
Applicability of dry powder inhalers in children with CF Source: International Congress 2016 – Cystic fibrosis: inflammation, microbiology, management and monitoring Year: 2016
Health status impact of ciprofloxacin dry powder for inhalation in patients with non-cystic fibrosis bronchiectasis Source: Annual Congress 2011 - Pseudomonas aeruginosa infection and non-cystic fibrosis bronchiectasis Year: 2011
Efficacy of inhaled dry powder tobramycin (TOBI Podhaler) in P. aeruginosa infected patients with bronchiectasis - iBEST study Source: Virtual Congress 2020 – Bronchiectasis: epidemiology, endotyping and therapy Year: 2020
Effect of I:E ratio on delivery of colistimethate sodium from breath-enhanced and breath-activated nebulizers Source: Annual Congress 2013 –Cystic fibrosis: basic and applied science Year: 2013
Inhaled bronchodilators in cystic fibrosis: a Cochrane review Source: Annual Congress 2006 - Cystic fibrosis lung disease: molecules images and drugs Year: 2006
Efficacy and safety of salbutamol delivered via a novel multidose dry powder inhaler in comparison with two conventional dry powder inhalers and a pMDI in asthmatic subjects Source: Eur Respir J 2001; 18: Suppl. 33, 50s Year: 2001
A study to evaluate the therapeutic equivalence of a new multidose budesonide dry powder inhaler with a conventional budesonide dry powder inhaler Source: Eur Respir J 2001; 18: Suppl. 33, 156s Year: 2001
Use of dry powder inhalers in COPD Source: Eur Respir J 2005; 26: Suppl. 49, 286s Year: 2005
Comparison of two dry powder inhalers containing budesonide in the treatment of asthma in children Source: Eur Respir J 2002; 20: Suppl. 38, 500s Year: 2002
Oral manifestations in asthmatic patients using metered dose inhaler and dry powder inhaler Source: International Congress 2019 – Innovations in primary care assessment and management Year: 2019
Once-daily tobramycin in the treatment of adult patients with cystic fibrosis Source: Eur Respir J 2002; 19: 303-309 Year: 2002
In vivo pulmonary deposition of aclidinium bromide from a multidose dry powder inhaler Source: Annual Congress 2008 - Novel treatments for respiratory disease Year: 2008
Pharmacokinetics and pharmacodynamics of beclomethasone dipropionate and formoterol combination after inhalation using a new dry powder inhaler Source: Eur Respir J 2007; 30: Suppl. 51, 350s Year: 2007